1. Home
  2. TDF vs ARMP Comparison

TDF vs ARMP Comparison

Compare TDF & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Dragon Fund Inc.

TDF

Templeton Dragon Fund Inc.

HOLD

Current Price

$10.81

Market Cap

289.1M

Sector

Finance

ML Signal

HOLD

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$7.02

Market Cap

295.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TDF
ARMP
Founded
1994
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
289.1M
295.5M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
TDF
ARMP
Price
$10.81
$7.02
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
70.3K
59.3K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.64
$1.81
52 Week High
$12.20
$14.98

Technical Indicators

Market Signals
Indicator
TDF
ARMP
Relative Strength Index (RSI) 40.35 36.87
Support Level $10.30 $4.96
Resistance Level $11.67 $7.70
Average True Range (ATR) 0.33 0.66
MACD -0.03 -0.00
Stochastic Oscillator 21.85 30.05

Price Performance

Historical Comparison
TDF
ARMP

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: